'Not Dead Yet'

At The New York Times' Prescriptions blog, Andrew Pollack says RNA interference "might not be dead yet." That Alnylam Pharmaceuticals recently announced it had established proof of concept for the efficacy of an RNAi-based drug in a phase 1 clinical trial "at least points to the possibility that the approach can be used in people," Pollack says.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.